NeuroBo Pharmaceuticals, Inc.
NASDAQ:NRBO
2.92 (USD) • At close October 21, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | NeuroBo Pharmaceuticals, Inc. |
Symbool | NRBO |
Munteenheid | USD |
Prijs | 2.92 |
Beurswaarde | 24,781,456 |
Dividendpercentage | 0% |
52-weken bereik | 2.08 - 6.75 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Hyung-Heon Kim |
Website | https://www.neurobopharma.com |
An error occurred while fetching data.
Over NeuroBo Pharmaceuticals, Inc.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)